Our cohort is substantially larger than other published studies on galectin-3: van Kimmenade et al. (5) (acute HF), Lok et al. (6) (mild, chronic HF), Milting et al. (7) (end-stage HF), and Lin et al. (8) (chronic HF); and the COACH cohort was characterized by a very high event rate: in the current subset of 592 HF patients, 248 patients reached the primary end-point, and 164 died. Here, LGALS3 is linked to hydrops fetalis.